Citations

Mayo Clinic

Showing 10 of 108522 citations.

THE RISE OF BULIMIA NERVOSA
Lucas, Alexander R. , Soundy, Timothy J.

Past, Present and Future of Psychiatry | November 27, 2014 | Volume: No volume available | Issue: No issue available | Pages: 701-703

10.1142/9789814440912_0147 Get It

Faculty Opinions recommendation of Transcription factor IRF5 drives P2X4R+-reactive microglia gating neuropathic pain.
Eyo, Ukpong B , Wu, Long‐Jun , Eyo, Ukpong B.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 26, 2014 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718384688.793501754 Get It

Electrophysiologic Characteristics of Ventricular Arrhythmias Arising from the Aortic Mitral Continuity—Potential Role of the Conduction System
Hai, Jo Jo , Chahal, C. Anwar A. , Friedman, Paul A. , Vaidya, Vaibhav R. , Syed, Faisal F. , Nanda, Sudip , Brady, Peter A. , Madhavan, Malini , Cha, Yong‐Mei , Mulpuru, Siva K. , Munger, Thomas M. , Packer, Douglas L. , Asirvatham, Samuel J. , DeSimone, Christopher V. , McLeod, Christopher J. , Asirvatham, Samuel J , Chahal, Choudhary Anwar A

Journal of Cardiovascular Electrophysiology | November 26, 2014 | Volume: 26 | Issue: 2 | Pages: 158-163

10.1111/jce.12587 | PMID 25425429 Get It

Arrhythmogenic Substrate of Ventricular Arrhythmias at the AMCIntroductionCatheter ablation of ventricular arrhythmia (VA) at the fibrous aortic mitral continuity (AMC) has been described, yet the nature of the arrhythmogenic substrate remains unknown.MethodsProcedural records of 528 consecutive patients undergoing ablation of VA at Mayo Clinic, Rochester, MN, were reviewed. The electrocardiographic and electrophysiologic characteristics of patients with successful ablation at the AMC were analyzed to characterize the underlying arrhythmogenic substrate.ResultsOf the 21 patients (mean age 53.2 ± 13.4 years, 47.6% male) who underwent ablation of VA at the AMC with acute success, prepotentials (PPs) were found at the ablation sites preceding the ventricular electrogram (VEGM) during arrhythmias in 13 (61.9%) patients and during sinus rhythm in 7 (53.8%) patients. VAs with PPs were associated with a significantly higher burden of premature ventricular complexes (PVCs; 26.1 ± 10.9% vs. 14.9 ± 10.1%, P = 0.03), shorter VEGM to QRS intervals (9.0 ± 28.5 milliseconds vs. 33.1 ± 8.8 milliseconds, P = 0.03), lower pace map scores (8.7 ± 1.6 vs. 11.4 ± 0.8, P = 0.001), and a trend toward shorter V‐H intervals during VA (32.1 ± 38.6 milliseconds vs. 76.3 ± 11.1 milliseconds, P = 0.06) as compared to those without PP. A strong and positive correlation was found between V‐H interval and QRS duration during arrhythmia in those with PPs (B = 2.11, R2 = 0.97, t = 13.7, P < 0.001) but not in those without PPs.ConclusionLocal EGM characteristics and relative activation time of the His bundle suggest the possibility of conduction tissue as the origin for VA arising from the fibrous AMC. Specific identification and targeting of PPs when ablating VAs at this location may improve procedural success.
Hydroxyapatite-reinforcedin situforming PLGA systems for intraosseous injection
Fisher, Paul D. , Venugopal, Ganesh, Milbrandt, Todd A. , Puleo, David A. , Hilt, J. Zach

Journal of Biomedical Materials Research Part A | November 26, 2014 | Volume: 103 | Issue: 7 | Pages: 2365-2373

10.1002/jbm.a.35375 | PMID 25424622 Get It

The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma
Cheng, Su-Chun, Margolin, Kim , Clark, Joseph I. , Sosman, Jeffrey A. , Logan, Theodore F. , Curti, Brendan D. , Wong, Michael K. , Oleksowicz, Leslie, Vaishampayan, Ulka N. , Mier, James W., Panka, David J., Bhatt, Rupal S. , Bailey, Alexandra S. , Leibovich, Bradley C. , Kwon, Eugene D., Kabbinavar, Fairooz F. , Belldegrun, Arie S., Figlin, Robert A. , Pantuck, Allan J., Regan, Meredith M. , McDermott, David F. , Cheng, Su–Chun, Signoretti, Sabina , Dutcher, Janice P. , Ernstoff, Marc S. , Appleman, Leonard J. , Khushalani, Nikhil I. , Atkins, Michael B. , Vaishampayan, Ulka

Clinical Cancer Research | November 26, 2014 | Volume: 21 | Issue: 3 | Pages: 561-568

10.1158/1078-0432.ccr-14-1520 | PMID 25424850 Get It

Abstract Purpose: High-dose aldesleukin (HD IL2) received FDA approval for the treatment of metastatic renal cell carcinoma (MRCC) in 1992, producing a 14% objective response rate (ORR) and durable remissions. Retrospective studies suggested that clinical and pathologic features could predict for benefit. The Cytokine Working Group conducted this prospective trial to validate proposed predictive markers of response to HD IL2. Experimental Design: Standard HD IL2 was administered to prospectively evaluate whether the ORR of patients with mRCC with “good” predictive pathologic features based on an “integrated selection” model [ISM (e.g., clear-cell histology subclassification and carbonic anhydrase-9 (CA-9) IHC staining] was significantly higher than the ORR of a historical, unselected population. Archived tumor was collected for pathologic analysis including tumor programmed death-ligand 1 (PD-L1) expression. Results: One hundred and twenty eligible patients were enrolled between June 11 and September 7; 70% were Memorial Sloan Kettering Cancer Center (New York, NY) intermediate risk, 96% had clear cell RCC, and 99% had prior nephrectomy. The independently assessed ORR was 25% (30/120, 95% CI, 17.5%–33.7%, P = 0.0014; 3 complete responses, 27 partial responses) and was higher than a historical ORR. Thirteen patients (11%) remained progression free at 3 years and the median overall survival was 42.8 months. ORR was not statistically different by ISM classification (“good-risk” 23% vs. “poor-risk” 30%; P = 0.39). ORR was positively associated with tumor PD-L1 expression (P = 0.01) by IHC. Conclusions: In this prospective, biomarker validation study, HD IL2 produced durable remissions and prolonged survival in both “good” and “poor-risk” patients. The proposed ISM was unable to improve the selection criteria. Novel markers (e.g., tumor PD L1 expression) appeared useful, but require independent validation. Clin Cancer Res; 21(3); 561–8. ©2014 AACR.
Identification of Hospital Outliers in Bleeding Complications After Percutaneous Coronary Intervention
Hess, Connie N. , McCoy, Lisa A., Spertus, John A. , Krone, Ronald J. , Weaver, W. Douglas, Peterson, Eric D., Rao, Sunil V. , Neely, Megan L, Neely, Megan Lee , Singh, Mandeep , Peterson, Eric D. , Spertus, John A

Circulation: Cardiovascular Quality and Outcomes | November 26, 2014 | Volume: 8 | Issue: 1 | Pages: 15-22

10.1161/circoutcomes.113.000749 | PMID 25424242 Get It

Background— Post-percutaneous coronary intervention (PCI) bleeding complications are an important quality metric. We sought to characterize site-level variation in post-PCI bleeding and explore the influence of patient and procedural factors on hospital bleeding performance. Methods and Results— Hospital-level bleeding performance was compared pre- and postadjustment using the newly revised CathPCI Registry ® bleeding risk model (c-index, 0.77) among 1292 National Cardiovascular Data Registry ® hospitals performing >50 PCIs from 7/2009 to 9/2012 (n=1 984 998 procedures). Using random effects models, outlier sites were identified based on 95% confidence intervals around the hospital’s random intercept. Bleeding 72 hours post-PCI was defined as: arterial access site, retroperitoneal, gastrointestinal, or genitourinary bleeding; intracranial hemorrhage; cardiac tamponade; nonbypass surgery–related blood transfusion with preprocedure hemoglobin ≥8 g/dL; or absolute decrease in hemoglobin value ≥3 g/dL with preprocedure hemoglobin ≤16 g/dL. Overall, the median unadjusted post-PCI bleeding rate was 5.2% and varied among hospitals from 2.6% to 10.4% (5th, 95th percentiles). Center-level bleeding variation persisted after case-mix adjustment (2.8%–9.5%; 5th, 95th percentiles). Although hospitals’ observed and risk-adjusted bleeding ranks were correlated (Spearman ρ: 0.88), individual rankings shifted after risk-adjustment (median Δ rank order: ±91.5; interquartile range: 37.0, 185.5). Outlier classification changed postadjustment for 29.3%, 16.1%, and 26.5% of low-, non-, and high-outlier sites, respectively. Hospital use of bleeding avoidance strategies (bivalirudin, radial access, or vascular closure device) was associated with risk-adjusted bleeding rates. Conclusions— Despite adjustment for patient case-mix, there is wide variation in rates of hospital PCI-related bleeding in the United States. Opportunities may exist for best performers to share practices with other sites.
Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors
Roulstone, Victoria , Khan, Khurum , Pandha, Hardev , Rudman, Sarah , Gill, George M., Melcher, Alan , Vile, Richard G. , Harrington, Kevin J. , Bono, Johann S. de , Spicer, James , Coffey, Matt C. , Melcher, Alan A , Harrington, Kevin , de Bono, Johann

Clinical Cancer Research | November 26, 2014 | Volume: 21 | Issue: 6 | Pages: 1305-1312

10.1158/1078-0432.ccr-14-1770 | PMID 25424857 Get It

Abstract Purpose: Reovirus is a wild-type oncolytic virus that is ubiquitous in the environment; most patients are therefore preimmune. Therapeutic administration leads to an increase in neutralizing antireovirus antibody (NARA) titer. We hypothesized that if NARA limited reovirus antitumor activity, the effect might be attenuated by coadministration of cyclophosphamide. Experimental design: In a phase I study, patients with advanced cancer received cyclophosphamide 3 days before intravenous reovirus serotype 3 Dearing (RT3D). The primary objective was to reduce the resulting rise in NARA titer. Cyclophosphamide dose was escalated from 25–1,000 mg/m2 through nine cohorts; we aimed to define a well-tolerated immunomodulatory dose. Results: The combination was well tolerated in 36 patients, with grade 3/4 toxicities only seen at or above the maximum tolerated dose of cyclophosphamide, which was 800 mg/m2 combined with reovirus. Immunosuppressive effect, defined as maintaining NARA titer rise below a predefined threshold, was observed in only one patient. Furthermore, despite expected myelosuppression seen at higher cyclophosphamide doses, no changes in T-cell subsets, including Tregs, occurred with dose escalation. Viable virus was detected in association with peripheral blood mononuclear cells (PBMC) from 14% of patients 10 days after the last RT3D injection, despite high plasma NARA titer, demonstrating a potential mechanism for prolonged evasion of neutralization by reovirus. Conclusions: Coadministration of cyclophosphamide with reovirus is safe, but does not attenuate host antiviral responses. Alternative immunomodulation approaches should be explored, but association with PBMCs may allow reovirus to persist and evade even high levels of neutralizing antibodies. Clin Cancer Res; 21(6); 1305–12. ©2014 AACR.
Experimental Sleep Restriction Causes Endothelial Dysfunction in Healthy Humans
Calvin, Andrew D. , Covassin, Naima , Kremers, Walter K. , Adachi, Taro, Macedo, Paula , Bukartyk, Jan , Davison, Diane E., Levine, James A. , Singh, Prachi , Wang, Shihan , Albuquerque, Felipe N. , Somers, Virend K. , Singh, Prachi , Calvin, Andrew D , Kremers, Walter K

Journal of the American Heart Association | November 25, 2014 | Volume: 3 | Issue: 6 | Pages: No page available

10.1161/jaha.114.001143 | PMID 25424573 Get It

Background Epidemiologic evidence suggests a link between short sleep duration and cardiovascular risk, although the nature of any relationship and mechanisms remain unclear. Short sleep duration has also been linked to an increase in cardiovascular events. Endothelial dysfunction has itself been implicated as a mediator of heightened cardiovascular risk. We sought to determine the effect of 8 days/8 nights of partial sleep restriction on endothelial function in healthy humans. Methods and Results Sixteen healthy volunteers underwent a randomized study of usual sleep versus sleep restriction of two‐thirds normal sleep time for 8 days/8 nights in a hospital‐based clinical research unit. The main outcome was endothelial function measured by flow‐mediated brachial artery vasodilatation ( FMD ). Those randomized to sleep restriction slept 5.1 hours/night during the experimental period compared with 6.9 hours/night in the control group. Sleep restriction was associated with significant impairment in FMD (8.6±4.6% during the initial pre‐randomization acclimation phase versus 5.2±3.4% during the randomized experimental phase, P =0.01) whereas no change was seen in the control group (5.0±3.0 during the acclimation phase versus 6.73±2.9% during the experimental phase, P =0.10) for a between‐groups difference of −4.40% (95% CI −7.00 to −1.81%, P =0.003). No change was seen in non‐flow mediated vasodilatation ( NFMD ) in either group. Conclusion In healthy individuals, moderate sleep restriction causes endothelial dysfunction. Clinical Trial Registration URL : ClinicalTrials.gov. Unique identifier: NCT 01334788.
Protein Electrophoresis and Immunofixation for the Diagnosis of Monoclonal Gammopathies
Kyle, Robert A. , Rajkumar, S. Vincent

JAMA | November 25, 2014 | Volume: 312 | Issue: 20 | Pages: 2160

10.1001/jama.2014.8237 | PMID 25423222 Get It

Comparing the Clinical Utility of the Infant Developmental Inventory With the Ages and Stages Questionnaire at 9-Month Well-Child Visits
Hunter, Lindsay R., Myszkowski, Mioki R., Johnson, Shirley K., Rostad, Paulette V., Weaver, Amy L. , Lynch, Brian , Lynch, Brian A

Journal of Primary Care & Community Health | November 25, 2014 | Volume: 6 | Issue: 3 | Pages: 193-198

10.1177/2150131914560228 | PMID 25424742 Get It

Objective: The purpose of our study was to compare the clinical utility of administering 2 recommended developmental screening instruments, the Infant Developmental Inventory (IDI) and the Ages and Stages Questionnaire (ASQ), at 9-month well-child visits in paper format. Methods: Outcomes of the 2 screens, including correct completion and interpretation by clinician, time of visit, and screen outcome were compared. Results: Out of 33 children administered the ASQ and with documented scores, 12 (36.4%) did not receive passing scores, while 5 (12.2%) of the 41 children administered the IDI did not receive passing scores ( P = .014). Out of 41 IDI screens, 12 (29.3%) were completed incorrectly, while there were no ASQ screens completed incorrectly ( P < .001) by caregivers. Conclusion: In our pilot study, the ASQ is more often completed correctly by caregivers and identifies more children at risk for delay as compared with the IDI. Additional larger scale studies are needed to evaluate the usefulness of developmental screening tools when used within primary care practice.